FDA Cleared New Diabetic Macular Edema Drug Study
The FDA has authorized an investigational new drug application for Surrozen to test SZN-8141 in patients.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Do you trust that new clinical drug trials will lead to better medical treatment outcomes?
The FDA has cleared an investigational new drug application for SZN-8141, a Wnt agonist and VEGF antagonist antibody developed to treat diabetic macular edema. Surrozen plans to use this regulatory milestone to trigger the second closing of a March 2025 private placement.
Why it matters
The clearance satisfies a critical financial condition for a private placement expected to raise $95.1 million in gross proceeds. These funds will support the upcoming DUET clinical study for the new therapeutic candidate.
The phase 2a portion of the upcoming study will enroll approximately 60 patients to compare two dose levels of SZN-8141 against Vabysmo. Patients in the phase 1b portion will undergo evaluation for three months following a single intravitreal injection.
The players
FDA
The FDA is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
Surrozen
Surrozen is a biotechnology company focused on discovering and developing tissue-regenerative therapeutics.
The details
SZN-8141 is designed as a dual-action Wnt agonist and VEGF antagonist antibody. The DUET study will examine safety, tolerability, and retinal function in treatment-naive patients.
Timeline
March 2025: Private placement agreement reached.
October 20, 2026: Expected second closing of private placement.
Q4 2026: Anticipated initiation of the DUET clinical study.
2027: Expected timeline for the release of initial clinical data.
Health Landscape
The study positions SZN-8141 as a competitive challenge to Vabysmo, the established standard of care in the current therapeutic landscape for diabetic eye disease. This move represents a broader industry effort to innovate beyond existing VEGF-targeted treatments for retinal conditions.
The launch of the DUET study may eventually offer patients with diabetic macular edema additional treatment options beyond current therapies. The trial focuses on treatment-naive patients, which could provide alternative pathways for those just beginning their care journey.
The takeaway
The FDA clearance marks the start of a significant research pipeline for a new antibody treatment. Investors and patients should monitor the trial progress as initial efficacy data is expected in 2027.
Further reading
Learn more about the latest research and treatments in the Diabetes section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that new clinical drug trials will lead to better medical treatment outcomes?
